EP2191015 - A METHOD FOR PREDICTING THE RESPONSE OF A TUMOR IN A PATIENT SUFFERING FROM OR AT RISK OF DEVELOPING RECURRENT GYNECOLOGIC CANCER TOWARDS A CHEMOTHERAPEUTIC AGENT [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 30.09.2011 Database last updated on 24.08.2024 | Most recent event Tooltip | 30.09.2011 | Application deemed to be withdrawn | published on 02.11.2011 [2011/44] | Applicant(s) | For all designated states Sividon Diagnostics GmbH Nattermann Allee 1 50829 Köln / DE | [2011/24] |
Former [2010/22] | For all designated states Siemens Healthcare Diagnostics GmbH Ludwig-Erhard-Strasse 12 65760 Eschborn / DE | Inventor(s) | 01 /
GEHRMANN, Mathias Schlebuscher Heide 13 51375 Leverkusen / DE | 02 /
BRASE, Jan Christoph Kastanienallee 16a 21255 Tostedt / DE | 03 /
SCHMIDT, Marcus Eleonorenstr. 28 55252 Mainz-kastel / DE | [2010/22] | Representative(s) | Meyers, Hans-Wilhelm, et al Von Kreisler Selting Werner ATTENTION : ADDRESS INACTIVE - USE ASS-NR - CDR / DE | [N/P] |
Former [2011/24] | Meyers, Hans-Wilhelm, et al Von Kreisler Selting Werner P.O. BOX 102241 50462 Köln / DE | ||
Former [2010/22] | Maier, Daniel Oliver Siemens AG CT IP Com E Postfach 22 16 34 80506 München / DE | Application number, filing date | 08787449.1 | 25.08.2008 | [2010/22] | WO2008EP61088 | Priority number, date | DE20071043455 | 12.09.2007 Original published format: DE102007043455 | EP20070122919 | 11.12.2007 Original published format: EP 07122919 | [2010/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2009033941 | Date: | 19.03.2009 | Language: | EN | [2009/12] | Type: | A1 Application with search report | No.: | EP2191015 | Date: | 02.06.2010 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.03.2009 takes the place of the publication of the European patent application. | [2010/22] | Search report(s) | International search report - published on: | EP | 19.03.2009 | Classification | IPC: | C12Q1/68 | [2010/22] | CPC: |
C12Q1/6886 (EP,US);
C12Q2600/106 (EP,US);
C12Q2600/112 (EP,US);
C12Q2600/158 (EP,US)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/22] | Title | German: | VERFAHREN ZUR VORHERSAGE DES ANSPRECHENS EINES TUMORS AUF EIN CHEMOTHERAPEUTIKUM BEI EINEM PATIENTEN MIT EINER WIEDER AUFTRETENDEN GYNÄKOLOGISCHEN KREBSERKRANKUNG ODER DEM RISIKO DER ENTWICKLUNG DAVON | [2010/22] | English: | A METHOD FOR PREDICTING THE RESPONSE OF A TUMOR IN A PATIENT SUFFERING FROM OR AT RISK OF DEVELOPING RECURRENT GYNECOLOGIC CANCER TOWARDS A CHEMOTHERAPEUTIC AGENT | [2010/22] | French: | PROCÉDÉ DE PRÉVISION DE LA RÉPONSE D'UNE TUMEUR À UN AGENT CHIMIOTHÉRAPEUTIQUE CHEZ UN PATIENT SOUFFRANT D'UN CANCER GYNÉCOLOGIQUE RÉCURRENT OU À RISQUE DE DÉVELOPPER UN CANCER GYNÉCOLOGIQUE RÉCURRENT | [2010/22] | Entry into regional phase | 15.03.2010 | National basic fee paid | 15.03.2010 | Designation fee(s) paid | 15.03.2010 | Examination fee paid | Examination procedure | 15.03.2010 | Examination requested [2010/22] | 25.05.2010 | Amendment by applicant (claims and/or description) | 26.10.2010 | Despatch of a communication from the examining division (Time limit: M06) | 06.05.2011 | Application deemed to be withdrawn, date of legal effect [2011/44] | 10.06.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2011/44] | Divisional application(s) | EP11164981.0 / EP2390370 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 26.10.2010 | Fees paid | Renewal fee | 20.08.2010 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2005033699 (NCC TECHNOLOGY VENTURES PTE LT [SG], et al) [X] 2-10,15 * abstract *; | [XY] - SORLIE T, "Molecular portraits of breast cancer: tumour subtypes as distinct disease entities", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (200412), vol. 40, no. 18, ISSN 0959-8049, pages 2667 - 2675, XP004661394 [X] 2-10,15 * abstract, chap. 3 on p. 2268-2669 and fig. 2, Chap 5. p. 2669-p. 2671, col. 1 and chap. 7 * [Y] 1,12 DOI: http://dx.doi.org/10.1016/j.ejca.2004.08.021 | [X] - DRESSMAN HOLLY K ET AL, "Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 FEB 2006, (20060201), vol. 12, no. 3 Pt 1, ISSN 1078-0432, pages 819 - 826, XP002472390 [X] 2-10,15 * abstract, Tab. 2 and 4 * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-05-1447 | [X] - ROUZIER ROMAN ET AL, "Breast cancer molecular subtypes respond differently to preoperative chemotherapy.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 AUG 2005, (20050815), vol. 11, no. 16, ISSN 1078-0432, pages 5678 - 5685, XP002472391 [X] 2-10,15 * abstract, p. 5679, col. 1 and p. 5680, col. 1 * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-04-2421 | [XY] - LEWIS MICHAEL J ET AL, "Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma", BMC CANCER, BIOMED CENTRAL, LONDON, GB, (20040622), vol. 4, no. 1, ISSN 1471-2407, page 27, XP021004625 [X] 11,13,14,16-18 * abstract * [Y] 1,12 DOI: http://dx.doi.org/10.1186/1471-2407-4-27 | [XY] - WIEBE JOHN P ET AL, "Activity and expression of progesterone metabolizing 5[alpha]-reductase, 20[alpha]-hydroxysteroid oxidoreductase and 3[alpha]([beta])-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells", BMC CANCER, BIOMED CENTRAL, LONDON, GB, (20030322), vol. 3, no. 1, ISSN 1471-2407, page 9, XP021016085 [X] 11,13,14,16-18 * abstract, p. 4 and tab. 1 * [Y] 1,12 DOI: http://dx.doi.org/10.1186/1471-2407-3-9 | [A] - BRENTON JAMES D ET AL, "Molecular classification and molecular forecasting of breast cancer: ready for clinical application?", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, (200510), vol. 23, no. 29, ISSN 0732-183X, pages 7350 - 7360, XP009096987 [A] 1-18 * page 7355; figure 2 * DOI: http://dx.doi.org/10.1200/JCO.2005.03.3845 | [A] - SEEBACH J ET AL, "A Molecular Profiling of Breast Cancer", SEMINARS IN BREAST DISEASE, SAUNDERS, PHILADELPHIA, PA, US, (2006), vol. 9, no. 1, ISSN 1092-4450, pages 19 - 24, XP009096977 [A] 1-18 * abstract, p. 20, cap. "breast cancer subtype" and p. 22, chap. "using gene signatures as a clinical tool" * |